engleski

Osteoprotegerin in postmenopausal women

Objective Osteoprotegerin has an important role in regulation of bone remodeling by blocking osteoclast differentiation, suppressing activation and stimulating its apoptosis. Altered production of osteoprotegerin is involved in the disorder of remodeling balance and bone loss in the postmenopause. In this study relationship of osteoprotegerin and standard bone markers was investigated in postmenopausal women. Material and methods This study comprised 42 healthy postmenopausal women. Densitometry by x-ray dual absorptiometry was used to assess bone status of the lumbar spine and left hip. Blood was drawn after an overnight fast for measurement of osteoprotegerin, bone alkaline phosphatase and C-terminal telopeptide of collagen type I. The sera were stored frozen until assayed. Commercial ELISA kits were used for measurement of biochemical parameters: Osteoprotegerin, Biomedica, Austria ; Alkphase-B, Metra Biosystems, USA ; Serum Crosslaps, Nordic Bioscience Diagnostics, Denmark. Results The women were aged 63.4 8.1 years (42-81 years) and the duration of menopause was 15.5 8, 6 years (2-34 years). T-score for the hip figured – 2.1 1.0 (-4.5 - -0.1) and for the spine – 2.7 1.2 (-5.3 - -0.2). Osteoporosis of the hip was found in 36% and of the spine in 58% of women. Bone alkaline phosphatse was 25.5 13.2 IU/L (3-62 IU/L), with increased levels in 12% of patients. Telopeptide figured 0.5 0.2 ug/L (0.1 – 1.2 ug/L) and increased levels were found in 2% of patients. Osteoprotegerin levels were 3.9 1.2 pg/mL (1.7 – 8.3 pg/mL). Statistically significant and positive correlation (r=0.33, p=0.04) was found for osteoprotegerin and age. However, no significant relationship was found with either bone markers, T-scores or duration of menopause. Also, osteprotegerin did not differ between groups of women with normal bone mass, osteopenia and osteoporosis. Conclusions Increase of osteoprotegerin with age in this group of postmenopausal women is in agreement with the existing literature data. Lack of association of osteoprotegerin with clinically established bone markers or other clinical bone-related data was probably caused by biological variance and relatively small sample. Assessment of posssible clinical significance of measurement of osteoprotegerin remains to be established.

osteoprotegerin; postmenopausal osteoporosis

nije evidentirano